Both in Biotechnology
Tarsus Pharmaceuticals vs Beam Therapeutics
Over the past year TARS returned +4.1% and BEAM returned +8.6%; their daily moves had a correlation of 0.32.
TARS +4.1% BEAM +8.6%Growth of $1, one year, split-adjusted
| Metric | TARS | BEAM |
|---|---|---|
| Price | $72.64 | $26.33 |
| Market cap | $3.40B | $2.72B |
| Today | −0.93% | +1.78% |
| 1 month | −2.4% | +2.6% |
| 6 months | +11.7% | −8.9% |
| Year to date | −11.3% | −5.0% |
| 1 year | +5.6% | +5.3% |
| Revenue growth (YoY) | +69.4% | −94.2% |
| Gross margin | 93.0% | 100.0% |
| Net margin | −10.7% | −25036.3% |
| P/E (TTM) | — | — |
| Price / sales | 5.6× | 17.4× |
| Net cash | $376.9M | $1.05B |
| Dividend yield | — | — |
| Volatility (60d) | 46.1% | 63.4% |
| Short % of float | 15.3% | 32.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).